A phase II clinical trial assessing BNT122 (autogene cevumeran)
Latest Information Update: 16 Jan 2024
At a glance
- Drugs Autogene cevumeran (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Malignant melanoma; Pancreatic cancer; Solid tumours; Triple negative breast cancer
- Focus Therapeutic Use
Most Recent Events
- 16 Jan 2024 New trial record
- 09 Jan 2024 According to BioNTech media release, this trial is planned to be initiated as early as late 2024.